Toxicity of Extended Adjuvant Therapy With Aromatase Inhibitors in Early Breast Cancer: A Systematic Review and Meta-analysis

A Population-Based Study of Cardiovascular Mortality Following Early-Stage Breast Cancer

(2017) Husam Abdel-Qadir et al.   JAMA Cardiology

Aromatase inhibitors alone or sequentially combined with tamoxifen in postmenopausal early breast cancer compared with tamoxifen or placebo – Meta-analyses on efficacy and adverse events based on randomized clinical trials

(2016) Lisa Rydén et al.   BREAST

Evolution in the eligibility criteria of randomized controlled trials for systemic cancer therapies

(2016) A. Srikanthan et al.   CANCER TREATMENT REVIEWS

The risk of myocardial infarction with aromatase inhibitors relative to tamoxifen in post-menopausal women with early stage breast cancer

(2016) Husam Abdel-Qadir et al.   EUROPEAN JOURNAL OF CANCER

Extending Aromatase-Inhibitor Adjuvant Therapy to 10 Years

(2016) Paul E. Goss et al.   NEW ENGLAND JOURNAL OF MEDICINE

Neither fixed nor random: weighted least squares meta-regression

(2016) T. D. Stanley et al.   Research Synthesis Methods

Do participants in adjuvant breast cancer trials reflect the breast cancer patient population?

(2015) Shaun Treweek et al.   EUROPEAN JOURNAL OF CANCER

Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials

(2015)   LANCET

Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trials

(2015)   LANCET

Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials

(2013)   LANCET

Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial

(2012) Christina Davies et al.   LANCET

High non-compliance in the use of letrozole after 2.5years of extended adjuvant endocrine therapy. Results from the IDEAL randomized trial

(2011) D.B.Y. Fontein et al.   EJSO

Adjuvant tamoxifen and exemestane in early breast cancer (TEAM): a randomised phase 3 trial

(2011) Cornelis JH van de Velde et al.   LANCET

Up-Front Use of Aromatase Inhibitors As Adjuvant Therapy for Breast Cancer: The Emperor Has No Clothes

(2009) Bostjan Seruga et al.   JOURNAL OF CLINICAL ONCOLOGY

Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial

(2008)   LANCET ONCOLOGY